key: cord-1002816-lmgs21vl authors: Reyes, Luis Felipe; Murthy, Srinivas; Garcia-Gallo, Esteban; Irvine, Mike; Merson, Laura; Martin-Loeches, Ignacio; Rello, Jordi; Taccone, Fabio S.; Fowler, Robert A.; Docherty, Annemarie B.; Kartsonaki, Christiana; Aragao, Irene; Barrett, Peter W.; Beane, Abigail; Burrell, Aidan; Cheng, Matthew Pellan; Christian, Michael D.; Cidade, Jose Pedro; Wanjiru Citarella, Barbara; Donnelly, Christl A.; Fernandes, Susana; French, Craig; Haniffa, Rashan; Harrison, Ewen M.; Ho, Antonia Ying Wai; Joseph, Mark; Khan, Irfan; Kho, Michelle E.; Kildal, Anders Benjamin; Kutsogiannis, Demetrios; Lamontagne, François; Lee, Todd C.; Li Bassi, Gianluigi; Revilla, Jose Wagner Lopez; Marquis, Catherine; Millar, Jonathan; Neto, Raul; Nichol, Alistair; Parke, Rachael; Pereira, Rui; Poli, Sergio; Povoa, Pedro; Ramanathan, Kollengode; Rewa, Oleksa; Riera, Jordi; Shrapnel, Sally; Silva, Maria Joao; Udy, Andrew; Uyeki, Timothy; Webb, Steve A.; Wils, Evert-Jan; Rojek, Amanda; Olliaro, Piero L. title: Clinical characteristics, risk factors and outcomes in patients with severe COVID-19 registered in the ISARIC WHO clinical characterisation protocol: a prospective, multinational, multicentre, observational study date: 2021-12-10 journal: ERJ Open Res DOI: 10.1183/23120541.00552-2021 sha: 7e11473fcde3c40a7a8f6c6dfc0a16bb7cfba243 doc_id: 1002816 cord_uid: lmgs21vl Due to the large number of patients with severe COVID-19, many were treated outside of the traditional walls of the ICU, and in many cases, by personnel who were not trained in critical care. The clinical characteristics and the relative impact of caring for severe COVID-19 patients outside of the ICU is unknown. This was a multinational, multicentre, prospective cohort study embedded in the ISARIC WHO COVID-19 platform. Severe COVID-19 patients were identified as those admitted to an ICU and/or those treated with one of the following treatments: invasive or non-invasive mechanical ventilation, high-flow nasal cannula, inotropes, and vasopressors. A logistic Generalised Additive Model was used to compare clinical outcomes among patients admitted and not to the ICU. A total of 40 440 patients from 43 countries and six continents were included in this analysis. Severe COVID-19 patients were frequently male (62.9%), older adults (median [IQR], 67 years [55, 78]), and with at least one comorbidity (63.2%). The overall median (IQR) length of hospital stay was 10 days (5–19) and was longer in patients admitted to an ICU than in those that were cared for outside of ICU (12 [6–23] versus 8 [4–15] days, p<0.0001). The 28-day fatality ratio was lower in ICU-admitted patients (30.7% [5797/18831] versus 39.0% [7532/19295], p<0.0001). Patients admitted to an ICU had a significantly lower probability of death than those who were not (adjusted OR:0.70, 95%CI: 0.65-0.75, p<0.0001). Patients with severe COVID-19 admitted to an ICU had significantly lower 28-day fatality ratio than those cared for outside of an ICU. Infections provided a framework for prospective observational data collection on hospitalised patients. The protocol, case report forms, consent forms and study information are available in the online supplement and in the ISARIC website (https://isaric.tghn.org). This is a standardized protocol for investigating severe acute infections of pathogens of public health interest with tiered data collection tailored to a range of resource settings. Investigators from 43 countries collected prospective data using the ISARIC CRF built on Research Electronic Data Capture (REDCap, version 8.11.11, Vanderbilt University, Nashville, Tenn.) hosted by the University of Oxford. Other investigators collected data on a variety of locally-hosted data systems and submitted data for centralised mapping to the ISARIC dataset. All investigators retain full rights to their data. This observational study required no change to clinical management and permitted patient enrolment in other research projects. The ISARIC-WHO Clinical Characterisation Protocol was approved by the World Health Organization Ethics Review Committee (RPC571 and RPC572). Local ethics approval was obtained for each participating country and site according to local requirements. Hospital-admitted patients included in the ISARIC database between January 17th and December 31st, 2020; this analysis was limited to those with laboratory-confirmed SARS-CoV-2 infection detected by reverse transcription polymerase chain reaction (rtPCR) in a respiratory sample analysed according to the sites' local diagnostic methods and protocols and classified as severe COVID-19. We used a modified WHO severity criteria [5] to categorize severe COVID-19 using the following criteria: patients treated with invasive or non-invasive mechanical ventilation, those treated with HFNC, and/or patients treated with vasopressors or inotropes; and/or patients treated within the ICU. Patients in whom more than 30% of the required clinical data variables were missing were excluded from the analysis. The primary outcome of this analysis was 28-day fatality ratio (from hospital admission date). The secondary outcomes were 90-day fatality ratio and hospital length-of-stay (LOS). Variables used in this analysis were age, sex, ethnicity (i.e., White, Black, Latino, Asian, Arab, other), symptoms, comorbidities, vital signs on admission, systemic complications, date of hospital admission, date of ICU admission, date of death, the requirement of advanced ventilatory support, treatment with vasopressors or inotropes, country of recruitment and its income classification according to the World Bank (https://data.worldbank.org/country). All the variables are listed in the study protocol and the online supplement. To study fatality ratios, only patients with a reported date of death were classified as dead. Patients that were still admitted at the point of data extraction were not included in the denominator to calculate the fatality ratio or other clinical outcomes. Only patients with a reported hospital discharge were included in calculating the hospital length of stay. All study variables were predefined in the ISARIC study protocol and case report form completion guide available online (https://isaric.tghn.org). The number of COVID-19 cases per million were obtained from the website Our World in Data (https://ourworldindata.org/coronavirus, access on April 12, 2021). The complete definitions of all variables were predetermined in the study protocol and are available in the online supplement. However, some definitions are provided here. Standards Consortium, Austin, Tex.) to integrate data collected on locally hosted databases with data collected on the ISARIC database. A bivariate analysis was initially carried out to compare the quantitative variables according to their distribution by other factors. If data were normally distributed, the Student's t-test was applied for independent samples; if the variable data were not normally distributed, Mann Whitney's U test was used. Categorical variables were compared by a Chi-square test. Variables were analysed by age, sex, date of hospital admission, and ICU admission. A logistic Generalised Additive Model (GAM) was fitted to assess the association of being admitted to the ICU with 28-day fatality ratio, adjusting for demographics (i.e., sex, and number of comorbidities), age treated as a non-linear continuous measure using a cubic spline, physiological variables on admission (i.e., heart rate, respiratory rate and blood pressure [systolic and diastolic blood pressure]) advance ventilatory support (i.e., HFNC, Non-invasive mechanical ventilation or Invasive Mechanical Ventilation), treatment with vasopressors or inotropes, the development of acute respiratory distress syndrome during hospital stay, month of admission, countries' income classification and new cases per million people per country at the moment of hospital admission. To further assess the non-linear associations of age, calendar time, and per-capita number of COVID-19 cases within a country with fatality ratio, a logistic GAM was fitted using 28-day fatality ratio as a dichotomous outcome. Further non-linear terms for age, comorbidities, calendar day, and COVID-19 cases per million in the affected country were modelled as cubic splines. A sensitivity analysis was constructed using the above GAM and excluding patients enrolled in the United Kingdom (the majority of paints included in the analysis were registered at this country) to control for the centre effect. A further sensitivity analysis was constructed by excluding all patients identified as admitted to ICU without any other advanced ventilator support or vasopressor. All data processing and statistical analysis were performed using Python [20] [21] [22] [23] [24] [25] [26] [27] [28] breaths per minute) ( Table 1) . Other differences were observed in the physiological variables among patients admitted and not admitted to the ICU ( Table 1) . The most frequently administered treatments were systemic antibiotics (87. 3% Table 3 . The overall 28-day fatality ratio in our cohort was 34.9% (13329/38126) and 37.7% (14394/38126) for 90-day fatality ratio (Figure 1, Table 1, Supplementary Figure 5 ). The 28day fatality ratio was 30.7% (5797/18831) in patients admitted to the ICU and 39.0% 8 (7532/19295) in patients cared for exclusively outside the ICU. The 90-day fatality ratio was 33.7% (6358/18831) in those admitted to ICU and 41.6% (8036/19295) in those cared for outside the ICU. The median (IQR) overall hospital length of stay (LOS) was 10 days (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) , which was longer in ICU patients (12 days [6-23] vs. 8 days [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] , p<0.0001) when compared to non-ICU patients ( Table 1) . Finally, the hospital LOS in survivors was 11 (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) days, and it was longer in ICU admitted patients (13 vs. 9 [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] , p<0.0001). A biphasic distribution of the number of cases and deaths was identified, with a peak between April and May and October and November 2020 (Supplementary Figure 3 and 4) . Patients older than 65 years were frequently diagnosed with severe COVID-19 and had a higher fatality ratio (Supplementary Figures 3 and 4) . After adjusting for confounding variables (i.e., age, number of comorbidities, sex, presence of ARDS, treatments [inotropes, vasopressors, HFNC, invasive and non-invasive mechanical ventilation], country's income classification, number of new cases per day in the relevant country and, physiological variables on hospital admission [heart rate, respiratory rate, systolic or diastolic blood pressure, and temperature]), patients admitted to the ICU had a lower risk of 28-day fatality ratio (OR:0.70, 95%CI: 0.65-0.75, p<0.0001) ( Table 4) Previously documented risk factors for death, including age, sex, prior comorbidities, and ARDS, were confirmed in our study (Table 4) . To test these results, we performed a sensitivity analysis with ethnicity (Supplementary Table 3 ), patients enrolment in the United Kingdom, sex, and age revealed a similar protective effect of ICU admission on 28-day and 90-day fatality ratios (Table 4, Table 2 ). Finally, we removed patients who were admitted to ICU who did not need advance ventilatory support (n=2716, Supplementary Figure 1) , confirming that patients admitted to the ICU had lower likelihood of dying. This analysis describes the clinical characteristics, symptoms, and outcomes from the largest prospective, multinational cohort of hospitalised patients with severe COVID-19. Worse clinical outcomes were seen in older, male, obese, patients with comorbidities and those who developed ARDS. Fatality ratios in patients hospitalised with severe COVID-19 changed over time, being higher during the initial weeks of the pandemic's first wave. Finally, we identified that severe COVID-19 patients admitted to ICU had lower 28-day and 90-day fatality ratios, independent of age, disease severity, number of comorbidities, countries' income classification, healthcare system saturation (i.e., number of new cases per day), and treatments received when compared with patients that were cared for outside of ICU. Previous studies have found that around 30% of patients infected with SARS-CoV-2 can develop severe disease requiring admission to an ICU or advanced ventilatory support, such as invasive, non-invasive mechanical ventilation, or HFNC.[10, [13] [14] [15] [16] Our study found that 32% of patients that required hospital admission developed severe COVID-19, which is in alignment with prior published data. Regarding the clinical characteristics of patients with severe COVID -19, Grasselli G et al. [11] reported that 82% of patients hospitalised in the Italian hospitals were male, with a median age of 63 years old, and frequently have several comorbidities. Xie J et al. [10] reported that severely ill patients in China had a median age of 63 years old; 65% were male and had a past medical history of cardiovascular diseases, specifically hypertension. Moreover, several studies have also confirmed the associations between age, sex and comorbidities and severe COVID-19 disease.[2, 3, 17, 18] Our findings are in concordance with our results, where the median admission age was 67.5 years old, and the majority of patients were male. We also found that most of patients who developed severe COVID-19 had at least one comorbidity, with hypertension, chronic cardiac diseases, and chronic pulmonary diseases being most frequent. During the pandemic, several pharmacological and non-pharmacological interventions have been used to treat patients with COVID-19. [5, 6, 19] The primary approach was to identify effective treatments by repurposing antiviral agents, immunomodulatory drugs, and medications with theoretical antiviral properties. However, this approach led to excessive use of interventions without evidence-based support, and the data supporting these interventions are controversial. [12, 20] To date, the only medications that have been consistently demonstrated to reduce fatality ratios in COVID-19 patients requiring oxygen supplementation are corticosteroids, specifically dexamethasone. [21, 22] In our study, patients received several medications and non-pharmacological interventions. Notably, we found that most patients were treated with systemic antibiotics and many other interventions, as reported previously in other studies. [23] This high antibiotic usage in patients with severe COVID-19 is concerning, because bacterial coinfection was not frequent in our cohort. Moreover, it is essential to highlight that only 28.3% of patients were treated with systemic corticosteroids, being more frequently used in patients admitted to the ICU. This might be explained by the fact that the RECOVERY trial results were published six months after the beginning of the pandemic, [22, 24] and pre-pandemic data did not support the use of corticosteroids by many international guidelines in patients with severe viral pneumonia. [25, 26] The COVID-19 pandemic has brought unprecedented challenges to healthcare systems around the world. [27] In many countries, ICU capacity was overwhelmed, requiring severely ill patients to be treated in non-ICU settings. [8, 9] Other studies have evaluated the utility of using non-invasive respiratory support in the general wards, showing that this treatment can be safely delivered outside of the ICU,[8] although outcomes were not compared with similar patients treated in an ICU. We found that treating patients in the ICU was associated with a lower fatality ratio after adjusting for a number of possible confounders, including the severity of illness. There is an important selection bias of patients admitted to ICU because clinicians tend to admit patients with a better survival probability. However, our results build on previous work that personnel trained in ICU care, and the presence of a higher nurse-to-patient ratio may significantly impact the fatality ratio in severely ill patients more than access to specific organ support interventions. [28] An interpretation regarding why the fatality ratio is different among patients admitted and not to the ICU is required. These data are novel and have not been reported previously in patients with severe COVID-19. However, in Hong Kong, during the SARS 2003 pandemic, it was reported that expanding ICU settings was associated with higher fatality ratios. [29] Intensive care is often defined by the nurse-to-patient ratio and monitoring by trained staff, which may be a determinant of our findings. [30] Notably, we do not have information regarding personnel training, the monitoring systems used, or the staff ratios caring for these patients. Our study has strengths and limitations that are important to acknowledge. First, the ISARIC COVID-19 dataset is composed mainly of patients enrolled in high-income countries. However, this is a large prospectively collected cohort of patients enrolled in more than 40 countries worldwide, strengthening these results' generalizability. We performed a sensitivity analysis which showed no difference across income groupings. Secondly, the decision not to admit a patient to the ICU may be based on several factors, including treatment restriction orders and the clinician's estimation of surviving; however, this information is not easily collected and was not available in our dataset. Not having these data limits the conclusions we may draw about the impact of ICU admission on clinical outcomes as it is a residual selection bias. Third, the definitions of what constituted an ICU varies per country and centre. We assumed that similar treatment and care were offered to all COVID-19 patients upon ICU admission. Notably, the identified protective effect of ICU admission was consistent in the entire cohort, even after sensitivity analyses. Forth, several variants have emerged during the pandemic in different parts of the world. These variants have different disease severity, and vaccines might have different protective effects, affecting overall mortality. However, we did not have information regarding the virus identified, and thus, we did not control for this, which is an important limitation. However, we control for admission date, which might indirectly control for these variables that appeared worldwide over the pandemic. Fifth, oxygen saturation and blood arterial gases are frequently used to determine severity and guide treatment in patients with COVID-19. However, in our study, we do not have these data in all patients, which is a limitation we need to recognize. Importantly, we have vital signs and systemic complications that allowed us to assess disease severity. Finally, as our study included patients from several countries and centres with high caseloads and resourced limitations, the analysis was limited by missing data, possibly biasing the ultimate results. More than 30% of hospitalised SARS CoV-2-infected patients develop severe COVID-19 with high fatality ratios. These patients frequently require advanced supportive treatments, which has imposed an unprecedented burden on healthcare systems worldwide. Providing high-quality care to severely ill patients is a complex endeavour that requires trained personnel, a designated setting, monitoring equipment, and specialized management. The results presented in this study warrant caution about treating severely ill patients outside of an ICU and encourage hospitals to find strategies for severely ill patients to be treated in an ICU by personnel trained for the role. Supplementary figure 1. Venn diagram presenting how treatments (i.e., High-flow nasal cannula, Invasive mechanical ventilation, non-invasive mechanical ventilation, vasopressors/inotropes, and admission to the intensive care) interact among patients included in the cohort. Venn diagram presenting how treatments (i.e., High-flow nasal cannula, Invasive mechanical ventilation, non-invasive mechanical ventilation, and vasopressors/inotropes) interact among patients included in the cohort, stratified by admission to the intensive care unit. Histogram representing the number of new cases (in yellow) and the number of deaths (in red), in all patients (A), in patients older than 65 years old (B), and patients younger than 65 years old (C), during the study period. Cumulative histogram presenting the number of patients discharged alive (green), patients who died (purple), and patients that remained hospitalised at the time of the data extraction. Panel, A represents all the patients included in the study, panel B patients older than 65, and panel C the patients younger than 65. Age is shown to be an essential factor for higher mortality in patients with severe COVID-19; however, patients admitted to the ICU have a lower mortality rate independently of the age (A). Even after adjusting by the number of new cases per million at the moment of hospital admission (B) and the interaction over time (C), the marginal 90-day mortality rate was lower in patients admitted to the ICU. COVID-19 CORE CASE REPORT FORM 02FEB2021 -COMPLETION GUIDE Page 1 of 20 This CRF is set up in modules to be used for recording data on the ISARIC_nCov Core Database or for independent studies. Module 1 and Module 2 complete on the first day of admission or on first day of COVID-19 assessment. Module 2 also complete on first day of admission to ICU or high dependency unit. In addition, complete daily for as many days as resources allow up to a maximum of 14 days. Continue to follow-up patients who transfer between wards. Module 3 (Outcome) complete at discharge or death  The CRF is designed to collect data obtained through examination, interview and review of hospital notes. Data may be collected prospectively or retrospectively if the patient is enrolled after the admission date.  Participant Identification Numbers consist of a 5 digit site code and a 4 digit participant number. You can obtain a site code and registering on the data management system by contacting ncov@isaric.org. Participant numbers should be assigned sequentially for each site beginning with 0001. In the case of a single site recruiting participants on different wards, or where it is otherwise difficult to assign sequential numbers, it is acceptable to assign numbers in blocks or incorporating alpha characters. E.g. Ward X will assign numbers from 0001 or A001 onwards and Ward Y will assign numbers from 5001 or B001 onwards. Enter the Participant Identification Number at the top of every page.  Printed paper CRFs may be used for later transfer of the data onto the electronic database.  If using paper CRFs, we recommend writing clearly in ink, using BLOCK-CAPITAL LETTERS.  Place an (X) when you choose the corresponding answer. To make corrections, strike through (-------) the data you wish to delete and write the correct data above it. Please initial and date all corrections.  Please keep all of the sheets for a single participant together e.g. with a staple or participant-unique folder.  Please transfer all paper CRF data to the electronic database. All paper CRFs needs to be stored locally, do not send any forms to us. Data are accepted only via secure electronic database.  Please enter data on the electronic data capture system at https://ncov.medsci.ox.ac.uk/. If your site would like to collect data independently, we are happy to support the establishment of locally hosted databases.  Please contact us at ncov@isaric.org if you need help with databases, if you have comments and to let us know that you are using the forms. Comorbidities present before the onset of COVID-19 and are still present. Do not include those that developed following the onset of COVID-19 symptoms. More detailed guidance is provided. For patients who were admitted to hospital with COVID-19 or symptoms consistent with possible COVID-19 infection, please enter details for the date of hospital admission. For patients with a clear alternative diagnosis leading to admission who subsequently acquired COVID-19, original admission date should be provided, but all subsequent references to admission should be taken as referring to day COVID-19 was first clinically suspected (or within the first 24 hours after first day of suspected or confirmed COVID-19 infection). Where a patient was admitted via multiple hospital departments, count admission from the time they came to the first department during the visit that led to their admission (e.g. arrival at the Emergency Department). Include any form of supplemental oxygen received using any methods. Please include any mechanical ventilation delivered following intubation or via a tracheostomy. Do not include patients who are breathing independently via a tracheostomy. Please include any positive-pressure treatment given via a tight-fitted mask. This can be continuous positive pressure (CPAP) or bi-level positive pressure (BIPAP). Please include any form of continuous renal replacement therapy or intermittent haemodialysis. References to 'worst result' refer to those furthest from the normal physiological range or laboratory normal range. Results that were rejected by the clinical team (e.g. pulse oximetry on poorly perfused extremities, haemolysed blood samples, contaminated microbiology results) should not be reported. The following measures should be considered as a single observation and entered together: Blood gas results: Please report the measures from the blood gas with the lowest pH (most acidotic). Blood pressure: Please report the systolic and diastolic blood pressure from the observation with the lowest mean arterial pressure (if mean arterial pressure has not been calculated, report the measurement with lowest systolic blood pressure). Respiratory rate: If both abnormal low and high rate observed, record the abnormally high rate. COVID-19 CORE CASE REPORT FORM 02FEB2021 -COMPLETION GUIDE Page 3 of 20 Select yes if patient has either clinically suspected or laboratory-confirmed SARS-CoV-2 /COVID-19 infection. Enrolment date: Date of enrolment into the study or for in-patients is the date that COVID-19 was first assessed as suspected or confirmed by a clinician. Please enter all that apply of the following choices which best describe the patient's ethnicity or major ethnic group at birth. Please exclude nationality as nations often include many different ethnic groups (For example, Singaporean is the nationality but the ethnic grouping within Singapore could be East Asian, South Asian etc.) Cross (X) all that apply. If 'Other' write the full name of the ethnic group of the patient. Please do not enter a letter or number corresponding to a local/national ethnicity coding system. If the patient's ethnicity is not known, please place a cross (X) in the 'Unknown' box. Post-partum: Defined as within six weeks of delivery. If the baby is positive for COVID-19 please complete a separate form for the baby as well. Onset date of first/earliest symptom: Please provide the date of patient reported onset of the first symptom that you clinically believe was related to this episode of COVID-19 infection. Where a patient was admitted via multiple hospital departments, count admission from the time they came to the first department during the visit that led to their admission (e.g. arrival at the Emergency Department). For patients with a clear alternative diagnosis leading to admission who subsequently acquired COVID-19 report the date of admission as the day they were admitted to the healthcare facility. For participants who return for re-admission to the same site, start a new form with the same Participant Identification Number. Please check "YES-admitted previously to this facility". Enter each re-admission as a separate entry in the electronic database. For participants who transfer between two sites that are both collecting data on this form, it is preferred to have the data entered by a single site as a single admission, under the same Participant Identification Number. When this is not possible, the first site should record "Transfer to other facility" as an OUTCOME, and the second site should start a new form with a new patient number and indicate "YES-transferred from other facility" in RE-ADMISSION. For participants who return for re-admission to the same site, start a new form with a different Participant Identification Number. Please check "YES-admitted previously to this facility" in the RE-ADMISSION section. Enter as a separate entry in the electronic database. COVID-19 CORE CASE REPORT FORM 02FEB2021 -COMPLETION GUIDE Page 4 of 20 Please provide details of clinical observations made as close to presentation/admission, or within 24 hours of admission. For observations not made immediately at admission, please record the first available data (patient reported and/or from medical records) within 24 hours of admission. For patients with a clear alternative diagnosis leading to admission who subsequently acquired COVID-19, complete these observations for the 24 hours after onset of symptoms of suspected or confirmed COVID-19 infection. Please enter the peripheral body temperature (rectal if < 3 months) in the space provided and indicate the unit of measurement, either degrees Celsius (°C) or Fahrenheit (°F). Enter the heart rate measured in beats per minute. This may be measured manually or by electronic monitoring. Enter the respiratory rate in breaths per minute. Manual rather than electronic measurement is preferred where possible (this is achieved by counting the number of breaths for one minute, counting how many times the chest rises within this time period). Record the highest respiratory rate documented on admission. Please enter the systolic blood pressure measured in millimetres of mercury (mmHg), in the relevant sections. For example, if the blood pressure is 120/85 mmHg, enter 120 in the section marked 'systolic BP'. Use any recognised method for measuring blood pressure. Diastolic BP Please enter the diastolic blood pressure measured in millimetres of mercury (mmHg), in the relevant sections. For example, if the blood pressure is 120/85 mmHg, enter 85 in the section marked 'diastolic BP'. Use any recognised method for measuring blood pressure. For all patients, irrespective of ventilation or supplemental oxygen requirement, please enter the percentage oxygen saturation (the percentage of haemoglobin binding sites in the bloodstream occupied by oxygen) at the time of admission. This may be measured by pulse oximetry or by arterial blood gas analysis. Sternal capillary refill time > 2 seconds? Sternal capillary refill time is measured by pressing on the sternum for five seconds with a finger or thumb until the underlying skin turns white and then noting the time in seconds needed for the colour to return once the pressure is released. COVID-19 CORE CASE REPORT FORM 02FEB2021 -COMPLETION GUIDE Page 5 of 20 Please provide details of clinical observations made as close to presentation/admission, or within 24 hours of admission. For observations not made immediately at admission, please record the first available data (patient reported and/or from medical records) within 24 hours of admission. For patients with a clear alternative diagnosis leading to admission who subsequently acquired COVID-19, complete these observations for the 24 hours after onset of symptoms of suspected or confirmed COVID-19 infection. If the exact date of the most recent dose of COVID-19 vaccine isn't available, please provide an estimate of the day the vaccine was given. Partial dates (e.g. Jan-2021) cannot be entered in the database. Steroids: Examples include prednisolone, betamethasone, dexamethasone, hydrocortisone, methylprednisolone, deflazacort and fludrocortisone (oral), budesonide, fluticasone (inhaled). Please record if any of these comorbidities existed prior to admission. In general, do not include past comorbidities that are no longer ongoing. Additional details are given below. Where example conditions are given, these are not intended to be exhaustive and other conditions of equivalent severity should be included. Please include any of coronary artery disease, heart failure, congenital heart disease, cardiomyopathy, rheumatic heart disease. Elevated arterial blood pressure diagnosed clinically, >140mmHg systolic or >90mmHg diastolic. Please include any of chronic obstructive pulmonary disease (chronic bronchitis, chronic obstructive pulmonary disease (COPD), emphysema), cystic fibrosis, bronchiectasis, interstitial lung disease, preexisting requirement for long term oxygen therapy. Do not include asthma. Clinician-diagnosed asthma Please include any of clinician-diagnosed chronic kidney disease, chronic estimated glomerular filtration rate < 60 mL/min/1.73m 2 , history of kidney transplantation This refers to patients for whom an attending clinician has assessed them to be obese -ideally but not necessarily with an objective measurement of obesity, such as calculation of the body mass index (BMI of 30 or more) or measurement of abdominal girth. This is defined as cirrhosis with portal hypertension, with or without bleeding or a history of variceal bleeding. This is defined as cirrhosis without portal hypertension or chronic hepatitis Please include any of splenectomy, non-functional spleen, and congenital asplenia. Please include any of cerebral palsy, multiple sclerosis, motor neurone disease, muscular dystrophy, myasthenia gravis, Parkinson's disease, stroke, severe learning difficulty Current solid organ or haematological malignancy. Please do not include malignancies that have been declared 'cured' ≥5 years ago with no evidence of ongoing disease. Do not include non-melanoma skin cancers. Do not include benign growths or dysplasia. COVID-19 CORE CASE REPORT FORM 02FEB2021 -COMPLETION GUIDE Page 7 of 20 Any long-term disorder of the red or white blood cells, platelets or coagulation system requiring regular or intermittent treatment. Do not include leukaemia, lymphoma or myeloma, which should be entered under malignancy. Do not include iron-deficiency anaemia which is explained by diet or chronic blood loss. History of laboratory-confirmed HIV infection. Indicate whether or not the patient is on ART (antiretroviral therapy). Please provide the most recent CD4 count, if available. Type 1 or Type 2 diabetes mellitus requiring oral or subcutaneous treatment. Please indicate whether Type 1 or Type 2..If HbA1c results are available from the last 6 months only, please provide the most recent value. This is defined as an inflammatory and degenerative diseases of connective tissue structures. It includes chronic arthropathies and arthritis, connective tissue disorders and vasculitides. This is defined as clinical diagnosis of dementia Patients currently receiving treatment for tuberculosis. Do not include latent tuberculosis. Any clinically identified deficiency in intake, either of total energy or of specific nutrients that led to a dietetic intervention or referral prior to the onset of COVID-19 symptoms. Do not include people who needed supplementary nutrition solely due to reduced intake during their current illness episode. Smoking at least one cigarette, cigar, pipe or equivalent per day before the onset of the current illness. Do not include smoke-free tobacco products such as chewed tobacco or electronic nicotine delivery devices. Other relevant risk factor List any significant risk factors or comorbidities that existed prior to admission, are ongoing, that are not already listed. Please enter the highest peripheral body temperature (rectal if < 3 months) recorded during the course of the day in the space provided and indicate the unit of measurement, either degrees Celsius (°C) or Fahrenheit (°F). Enter the heart rate measured in beats per minute. This may be measured manually or by electronic monitoring. Enter the respiratory rate in breaths per minute. Manual rather than electronic measurement is preferred where possible (this is achieved by counting the number of breaths for one minute, counting how many times the chest rises within this time period). If both abnormal low and high rate observed, record the abnormally high rate. Please report the systolic and diastolic blood pressure from the observation with the lowest mean arterial pressure (if mean arterial pressure has not been calculated, report the measurement with lowest systolic blood pressure). Please enter the systolic blood pressure measured in millimetres of mercury (mmHg), in the relevant sections. For example, if the blood pressure is 120/85 mmHg, enter 120 in the section marked 'systolic BP'. Use any recognised method for measuring blood pressure. Please enter the diastolic blood pressure measured in millimetres of mercury (mmHg), in the relevant sections. For example, if the blood pressure is 120/85 mmHg, enter 85 in the section marked 'diastolic BP'. Use any recognised method for measuring blood pressure. For all patients, irrespective of ventilation or supplemental oxygen requirement, please enter the percentage oxygen saturation. This may be measured by pulse oximetry or by arterial blood gas analysis. This is a key indicator to complete for all patients. If the patient received any form of supplemental oxygen through a mask or nasal cannula that delivers a known concentration of oxygen or is being ventilated, please provide the fraction of inspired oxygen (FiO 2 ) delivered. For patients receiving oxygen through any means, such as a face mask or nasal cannula, that does not deliver a known oxygen concentration provide the maximum flow rate received on day of completion in L/min. PaO 2 (partial pressure of oxygen in blood) as determined by arterial/ capillary blood gas analysis. This PaO 2 must correspond with the oxygen therapy documented in the FiO 2 field. Please fill in the lowest value in either mmHg or kPa depending on the output of your blood gas analyser. If the PaO 2 is not known, place NA in the data field. PaCO 2 is the partial pressure of carbon dioxide measured in the sample. pH is the measure of the activity of the (solvated) hydrogen ion (H+) measured in the sample. HCO 3 -refers to the bicarbonate measured in the blood gas sample. Base excess refers to standardised base excess (SBE). If standardised base excess is not reported, enter the base excess value presented, this can be either a positive or negative value. Sternal capillary refill time is measured by pressing on the sternum for five seconds with a finger or thumb until the underlying skin turns white and then noting the time in seconds needed for the colour to return once the pressure is released. Alert -responding to voice -responding to pain -unresponsive: please state the least responsive condition of the patient during the calendar day (not counting normal sleep). On day of admission record the value as close to admission as possible before treatments have been administered. For daily records, if the patient is being sedated on the day of assessment record the value before the sedation. Please state the lowest GCS recorded. For intubated patients and patients with a non-fenestrated tracheostomy, give 1 point for the voice component and calculate the total as usual. Suffixes such as t for tracheostomy cannot be entered on to the database. If the patient is sedated on the day of assessment these parameters should correspond to the values observed before sedation. For daily recording, if the patient is fully sedated for the duration of the day of assessment (from 00:00 to 24:00) record non testable. Glasgow Coma Score: https://www.glasgowcomascale.org/downloads/GCS-Assessment-Aid-English.pdf?v=3 RASS -If done, enter the lowest calculated value (between -5 and 4) on the date of assessment. Please record all laboratory results available on day of admission, or the day that COVID-19 was first clinically suspected in patients already admitted to hospital, and on day of admission to ICU/HDU. For daily records: record the date of assessment as the day the blood sample/s were taken.. If the unit of measurement is not shown on the paper form it will likely appear in the dropdown list in the eCRF. If you cannot find the correct unit on the eCRF please use a unit converter, such as: http://unitslab.com/ or equivalent or email ncov@isaric.org to let us know. 'Worst value' refers to values furthest from the normal physiological range or laboratory normal range. Results that were rejected by the clinical team (e.g. haemolysed blood samples, contaminated microbiology results) should not be reported. Haemoglobin (Hb or Hgb) refers to haemoglobin concentration measurement in blood. WBC count is the total white blood cell count in blood. Haematocrit (Ht or HCT), also known as packed cell volume (PCV) or erythrocyte volume fraction (EVF), is the volume percentage (%) of red blood cells in blood. APTT is the activated partial thromboplastin time. Record the highest value. APTR is the activated partial thromboplastin ratio. If the patient received non-invasive ventilation (NIV), defined as the provision of ventilatory support through the patient's upper airway using a mask or similar device, at any time during their hospital stay, place tick 'yes' and enter the total duration in days if known. Invasive ventilation means that patient has undergone tracheal intubation, for the purpose of invasive mechanical ventilation. Invasive ventilation is a method to mechanically assist or replace spontaneous breathing in patients by use of a powered device that forces oxygenated air into the lungs. The mode of intubation may be orotracheal, nasotracheal, or via a cricothyrotomy or tracheotomy. Prone ventilation refers to ventilation with the patient lying in the prone position. If the patient received prone ventilation at any time during their hospital stay, please tick 'yes' and indicate the total duration in days. Please select all that were clinically identified at any time during the hospital admission. Do not include known comorbidities (e.g. previous atrial fibrillation should not be included but new onset during this admission should). Record physician diagnosed complications. Clinically or radiologically diagnosed viral pneumonitis/pneumonia. Clinically or radiologically diagnosed bacterial pneumonia (including community, hospital and ventilator acquired) managed with antimicrobials. Bacteriological confirmation not required. Defined according to Berlin criteria as:  Occurring within 1 week of a known clinical insult or worsening respiratory symptoms  Bilateral radiological opacities not fully explained by effusions, lobar/lung collapse, or nodules  Respiratory failure not fully explained by cardiac failure or fluid overload Is defined as the abnormal presence of air in the pleural cavity (between the lungs and the chest wall), causing collapse of the lung. It may be diagnosed clinically, usually with radiological confirmation. Is defined as increased amounts of fluid within the pleural cavity. It may be diagnosed clinically, with or without radiological or interventional confirmation. Idiopathic diffuse interstitial lung disease, diagnosed radiologically (multiple consolidative or ground glass opacities) or histologically (granulation tissue and chronic inflammatory infiltrate in alveoli). Formerly known as bronchiolitis obliterans organizing pneumonia (BOOP) This is a clinical diagnosis. Sudden cessation of cardiac activity with no normal breathing and no signs of circulation. Myocardial ischaemia (MI) leading to injury/necrosis, diagnosed by clinical findings, altered electrocardiography and elevated cardiac enzymes. Is defined as diminished blood and oxygen supply to the heart muscle, also known as myocardial ischemia, It is confirmed by an electrocardiogram (showing ischaemic changes, e.g. ST depression or elevation) and/or cardiac enzyme elevation. If a cardiac arrhythmia is identified and there is no previous record of it, select 'yes'. Rhabdomyolysis is a syndrome characterised by muscle necrosis and the release of myoglobin into the blood. Muscle biopsy, electromyography, radiological imaging and the presence of myoglobinuria are not required for the diagnosis. Myositis may be a clinical diagnosis with supporting evidence from laboratory tests e.g. elevated serum creatine kinase; histological confirmation is not required to make the diagnosis. Myositis can occur without progression to rhabdomyolysis. Acute renal injury is defined as any of:  Increase in serum creatinine by ≥0.3 mg/dL (≥26.5 µmol/L) within 48 hours  Increase in serum creatinine to ≥1.5 times baseline, which is known or presumed to have occurred within the prior 7 days  Urine volume <0.5 mL/kg/hour for 6 hours Refers to bleeding originating from any part of the gastrointestinal tract (from the oropharynx to the rectum). Inflammation of the pancreas, diagnosed from clinical, biochemical, radiological or histological evidence. A finding that indicates abnormal liver function, may refer to any of the following:  Clinical jaundice  Hyperbilirubinaemia (blood bilirubin level twice the upper limit of the normal range)  An increase in alanine transaminase or aspartate transaminase that is twice the upper limit of the normal range For adults, is defined as an abnormally high level of glucose in the blood, blood glucose level that is consistently above 126mg/dL or 7 mmol/L. For children, is defined as a blood glucose level consistently above 8.3 mmol/L. For adults, is defined as an abnormally low level of glucose in the blood, a blood glucose level that is consistently below 70mg/dL or 4 mmol/L. For children, is defined as a blood glucose level below 3 mmol/L. Please specify other complications in the space provided. ISARIC CCP Version 3.2 If you make modifications/translations/improvements we would be grateful if you would consider sharing these -however minor they are -with the international community through ISARIC. Background and Objectives ........................................................................................... 4 Study ............................................................................................................... 4 1.2 Background Information ......................................................................................................... 4 1.3 Target Audience of this Document .......................................................................................... 4 1.4 Source of this Protocol ............................................................................................................ 4 1.5 Primary Objectives .................................................................................................................. 4 1.6 Secondary Objectives .............................................................................................................. 5 : stratified recruitment according to local resource. ..................... 5 1.8 Entry Criteria ........................................................................................................................... 7 2. Study Design ............................................................................................................ ....................................................................................................................... 8 .................................................................................. .................................................................................................................. 9 .............................................................................. 9 Schedules.................................................................................... 9 3.5. ............................................................................ 19 ................................................................................... ...................................................................................................... 20 Analysis............................................................................. 20 .............................................................................................................. 21 This is a standardized protocol for the rapid, coordinated clinical investigation of severe or potentially severe acute infections by pathogens of public health interest. Patients with acute illness suspected to be caused by emerging and unknown pathogens will be enrolled. This protocol has been designed to enable data and biological samples to be prospectively collected and shared rapidly through a globally-harmonised sampling schedule. Multiple independent studies can be easily aggregated, tabulated and analysed across many different settings globally. The protocol is the product of many years of discussion among international investigators from a wide range of scientific and medical disciplines (Lancet ID 14 (1) Infectious disease is the single biggest cause of death worldwide. New infectious agents, such as the SARS, MERS and other novel coronavirus, novel influenza viruses, viruses causing viral haemorrhagic fever (e.g. Ebola), and viruses that affect the central nervous system (CNS) such as TBEV & Nipah require investigation to understand pathogen biology and pathogenesis in the host. Even for known infections, resistance to antimicrobial therapies is widespread, and treatments to control potentially deleterious host responses are lacking. In order to develop a mechanistic understanding of disease processes, such that risk factors for severe illness can be identified and treatments can be developed, it is necessary to understand pathogen characteristics associated with virulence, the replication dynamics and in-host evolution of the pathogen, the dynamics of the host response, the pharmacology of antimicrobial or hostdirected therapies, the transmission dynamics, and factors underlying individual susceptibility. The work proposed here may require sampling that will not immediately benefit the participants. It may also require analysis of the host genome, which may reveal other information about disease susceptibility or other aspects of health status. This document is of primary interest to clinicians (including emergency and critical care providers) and others engaged in identification, triage and treatment of patients with severe acute or potentially severe infections due to the pathogens of interest. Any individuals or members of research units/networks are invited to use this document to facilitate their own studies and contribute data to the centralized database. We encourage any and all centres to contribute to this effort. The primary data remain with the individual sites but we hope by collecting similar data investigators will be willing to share their results and allow a much more complete analysis of the data. This document is a product of collaboration between the World Health Organization (WHO) and the International Severe Acute Respiratory and Emerging Infections Consortium (ISARIC), and builds on a global consensus on observational research in emerging infections of public health interest. In potential participants meeting the entry criteria, our primary objectives for each individual pathogen are to:  Describe the clinical features of the illness or syndrome and identify risk factors for severe disease.  Describe, where appropriate, the response to treatment, including supportive care and novel therapeutics.  Observe, where appropriate and feasible, pathogen replication, excretion and evolution, within the host, and identify determinants of severity and transmission using high-throughput sequencing of pathogen genomes obtained from respiratory tract, blood, urine, stool, CSF and other samples.  Characterise, where appropriate and feasible, the host responses to infection and therapy over time, including innate and acquired immune responses, circulating levels of immune signalling molecules and gene expression profiling in peripheral blood.  Identify host genetic variants associated with disease progression or severity  Understand transmissibility and the probabilities of different clinical outcomes following exposure and infection Secondary objectives are to collect evidence in order to: The study will be conducted at multiple sites (to be determined by the spread of disease and availability of resources). It is appreciated that settings will vary in terms of clinical infrastructure, resources and capacity. Distinction is made to allow for resource-appropriate implementation of the protocol, and it is understood that data and/or specimen collection may be limited in certain settings. Observational analyses will be stratified according to available samples and data. Outcome data for primary and secondary objectives will be derived from (i) data from routine clinical and laboratory assessments performed as part of standard inpatient medical management at the treating site, documented using proportionate case report forms (CRF; either paper or web-based electronic 'eCRF'), with or without (ii) additional biological samples obtained for research purposes (depending on which tier of the protocol the site is recruiting to). Implementation of data and biological sample collection are classified into the following tiers:  TIER 0 (data collection only): Routine clinical and laboratory data will be collected but no biological samples will be obtained for research purposes. The minimum clinical data set will summarise the illness episode and outcome, with the option to collect additional detailed clinical data at frequent intervals, according to local resources/needs.  TIER 1 (1 biological sample set): Clinical samples will be collected on recruitment day (Day 1; ideally at initial presentation to a health care facility) but subsequent serial samples will not be obtained. Clinical information will be collected at recruitment and discharge.  TIER 2 (Serial biological sampling, schedules 2-11): Clinical samples and data will be collected on recruitment day (Day 1; ideally at initial presentation to a health care facility) followed by serial samples obtained at timepoints defined by the schedule (illustrated in Tables 2-5 ). The schedule ranges from 2 (recruitment and day 3) to 11 sample sets (recruitment, every second day for the next 14 days, then weekly [until maximum 100 days], then convalescent samples 3 & 6 months after recruitment). An interactive web app summarises the various schedules: https://isaric.net/ccp/  TIER 3 (Population pharmacokinetics of antimicrobial/immunomodulatory drugs) Each site will recruit at a given tier. This will be recorded in the site file, where the investigator will complete the "Tier Record Form". Any changes to the tier a given site is recruiting to will be documented by the Principal Investigator (PI). As an outbreak progresses, and more cases occur, it is anticipated that both the research priorities and the local resource availability will change. Within a given institution, cases recruited at different stages of an outbreak can be sampled at different intensities and may be recruited to different tiers of the study. This study will enrol eligible patients (children and adults) with confirmed or suspected infection with a pathogen relevant to the study objectives. Recruitment of patients with Day 1 (enrolment) data and biological samples is the priority. The local study team will dictate whether laboratory confirmation of infection is required prior to enrolment. Daily follow-up and convalescent visits of patients should proceed according to local resources. Suspected or proven infection with an emerging pathogen. Confirmed diagnosis of a pathogen unrelated to the objectives of this study (or other non-infectious diagnosis) and no indication or likelihood of co-infection with a relevant pathogen. Refusal by participant, parent or appropriate representative. This protocol is for a prospective observational cohort study. This is a descriptive study of a syndrome, which may be caused by a number of different known or poorly understood pathogens. Therefore, the sample size is not prospectively determined. Recruitment of participants will depend on the emergence and spread of the various pathogens and the resources available to the recruitment centres. The sample size will vary for each location but Number of cases included should be as large as feasible and preferably without limit in order to capture as much clinical data as possible early in the outbreak. This protocol will be opened at sites with capacity and capability to recruit to any tier of study intensity. The study has no set end date. In hospital, potential participants will be identified through hospital workers upon presentation at recruiting sites and through public health agencies. When resources limit the number of patients enrolled to less than the number of patients presenting, sites should establish procedures to minimize bias in the selection of participants. This requires collection of limited clinical data from the routine health record in a form that does not identify the patient. This does not generally require consent. Patients will only be considered for enrolment if appropriate local infection control and prevention measures are in place and can be maintained. When it has been decided that biological sampling can be performed safely and appropriate consent has been obtained, samples taken early may be most useful for identification or evaluation of risk factors for disease progression at a clinically-relevant decision point. Therefore it is desirable to begin sampling as early as possible during a patient's illness. Where patients lack capacity to consent to participation, an appropriate representative/consultee/parent/guardian will be approached by staff trained in consent procedures that protect the rights of the patient, and adhere to the ethical principles within the Declaration of Helsinki. Staff will explain the details of the study to the participant or parent/guardian/consultee and allow them time to discuss and ask questions. The staff will review the informed consent form with the person giving consent and endeavour to ensure understanding of the contents, including study procedures, risks, benefits, the right to withdraw and alternatives to participation. The consenting party will be asked to sign and date an informed consent form. If the patient is a child, the person with parental responsibility and the child, if competent, should both provide consent/ assent. In view of the importance of early samples, participants or their parent/guardian/consultee will be permitted to consent and begin to participate in the study immediately if they wish to do so. Those who prefer more time to consider participation will be approached again after an agreed time, normally one day, to discuss further. An outbreak involving a pathogen of public health interest or pandemic is an emergency. Patients who are incapable of giving consent in emergency situations are an exception to the general rule of informed consent in clinical research. This is clearly acknowledged in the Declaration of Helsinki (2008). The process of consent will comply with the principles of Good Clinical Practice and with the laws regulating clinical research in the recruiting centre. For studies that collect or collate only anonymised data that is normally collected, as part of routine care, consent may not be required. An internal pilot study will only collate data that is being recorded or generated as part of routine clinical care (e.g. microbiology results). We will seek consent, be it deferred, proxy or assent, in order to test the processes within the overarching Clinical Characterisation Protocol, which include obtaining consent. All patients will be treated according to clinical requirements regardless of their participation in the study. Provision of care will vary by site and by treating physician. It is not possible to define a single standard of care and therefore to define what samples will be taken as a part of medical management and when. Participants in Tiers 1 to 3 of this study may have samples taken in addition to those required for medical management. The results of tests performed on research samples are unlikely to benefit the health of the participants. Samples and data will be collected according to the protocol tier approach, available resources and the weight of the patient, to prevent excessive volume sampling from children, young people and small adults. Samples required for clinical management will at all times have priority over samples taken for research tests. Aliquots or samples for research purposes should never compromise the quality or quantity of samples required for medical management. Wherever practical, taking research samples should be timed to coincide with clinical sampling. The research team will be responsible for sharing the sampling protocol with health care workers supporting patient management in order to minimise disruption to routine care and avoid unnecessary procedures. Some samples should be processed and stored at -80°C (Table 1) . We recognise that -80°C storage is not available at all sites. In this case please store at coldest available temperature and at least -20°C. For patients with VHF such as Ebola virus, the biological sampling will at times be limited to extra volumes of blood taken at times to coincide when blood is being taken for clinical purposes and then only at the discretion of the clinical team. *freeze at -80°C where possible, or at least at -20°C. Further details of processing are provided in Table 9 . Collect data using CRF only. As you are collecting CRF data only and not biological samples, ethical approval or consent is generally not required. A single sample set is obtained at, or as soon as practical after, recruitment ('recruitment sample set'). Collect data using CRF. A 'recruitment sample set' is obtained followed by schedule-dependent 'serial sample sets' and one 'convalescent sample set' are obtained. Collect data using CRF. Example Tier 2 sampling schedules are shown below and all schedules are in Appendix 2. Key (refer to Table 1) : R: recruitment sample set S: serial sample set P: pathogen-only sample set C: convalescent samples *In the event that local resource limitations require sampling frequency to decrease, samples will be prioritised as shown (1=highest priority). Serial sampling will stop when acute illness resolves, or a patient is discharged from hospital: next samples taken will be the blood sample at 3 months and 6 months post recruitment. No patient will give more than 0.6ml/kg (>1% blood volume) on any one day, or more than 2.4ml/kg (approx 3% blood volume) in any four week period (MCRN recommendations). When a lumbar puncture is clinically-indicated and performed in an infant or older patient, an additional sample of up to 5mls of CSF will be collected in a separate universal sterile tube, provided it is deemed appropriate by the supervising clinician. The volume of CSF taken from a child younger than an infant See table 7 (below) for guidance on total safe volumes of CSF to take at lumbar puncture will be at the discretion of the attending clinician. Any residual CSF from samples taken as part of routine clinical care will be collected and stored Clinicianrequested pathogen samples (all patients) Where possible, we will obtain an aliquot of any residual and unwanted sample volume from specimens that have been sent by clinicians for pathogen detection, including those obtained before recruitment to the study: urine; stool; respiratory tract samples (NPA, ETA, BAL, sputum, ENT swabs); cerebrospinal fluid If after recruitment a lumbar puncture is clinically indicated, an additional sample of up to 5mls ( Table 7) will be collected in a universal sterile tube, provided it is deemed appropriate by the supervising clinician. Any residual CSF from samples taken as part of routine clinical care will be collected and stored if available. This will allow:  Extraction of RNA/DNA from causative pathogens and other circulating pathogens for molecular testing, genomic studies and virus isolation  Serological testing for pathogen-specific antibodies  Testing for mediators, metabolites and potential biomarkers In addition to the tier and sampling schedule decided by the PI, optional sub-studies from Table 8 can be included. Table 9 . Quantify nature and duration of humoral immunity. T-cell and B-cell receptor sequencing. 120mL 0.9% saline BAL, performed on days 1, 3 and 9. Centrifugation to obtain cell pellet and supernatant. Storage at -80°C. Study host immune response, viral replication and coinfection *separate consent forms are provided for these sub-studies which should be used in addition to the full consent form. In small numbers of patients with refractory respiratory failure due to SARI receiving extra-corporeal membrane oxygenation (ECMO) in a specialist centre, the opportunity exists to safely perform serial bronchoscopy for research purposes without the risk of impairing oxygenation (in contrast to bronchoscopy performed when oxygenation is dependent on mechanical ventilation). This is also safer for the operator since the patient can be paralysed and ventilation can be temporarily discontinued, reducing aerosol generation. Broncho-alveolar lavage specimens obtained in this context could be processed to allow analysis of viral load, bacterial or fungal co-infection, and host soluble immune mediators in the distal airway. In a small number of patients (likely to be less than 10 patients for each emerging infection) there is a need for additional sampling after recovery from acute illness to enable generation of serological tests, setting of reference standards for serology, extraction and culture of peripheral blood mononuclear cells (PBMCs) for cellular immunology studies, and generation of monoclonal antibodies for research, diagnostic and therapeutic use. These studies are often extremely valuable in the global response to a new pathogen. Immune cells, including monocytes, monocyte-derived macrophages, neutrophils and lymphocytes will be isolated from peripheral blood and studied immediately or following culture. Gene expression, protein synthesis and degradation, cytokine release and other functional studies will be measured in immune cells from cases and age-and sex-matched controls. Cells will be stored for future use and may be used in the generation of commercial products. Patients who participated, with appropriate consent, in this study may be invited to provide additional samples under separate consent for this part of the study. All blood samples will be obtained by an experienced phlebotomist. Participants will be fully recovered, otherwise healthy individuals with no contraindications to blood donation, including: • Infection with any blood borne diseases (e.g. HIV, Hepatitis B or Hepatitis C) Depending on the participant's weight, the following maximum volumes of blood will be obtained: • >40kg: 240mls (6.0mls/kg) • 20-40kg: 80mls (4.0mls/kg) Patients who satisfy the inclusion/exclusion criteria and have given informed consent to participate directly, or have been consented by a parent/guardian or whose wishes have been declared by a consultee, or be it deferred, proxy or assent, will be enrolled to the study. All patients will have clinical information collected either directly through examination including a review of medical, contact and travel history, or from available medical notes. Information will be recorded in the case report form. At enrolment, sites with available resources will: 1. Separate and store an aliquot of all routine clinical samples taken at baseline/presentation including (as indicated) blood, cerebrospinal fluid (if CNS disease), infected sites/sores, sputum, respiratory tract specimens, urine and stool or rectal swab. Any research pathogen samples which have not been taken for clinical care will be collected. 2. Take a blood sample (0.8 -15ml dependent on weight). The day of initial sample collection will be counted as Day 1. All study days will be counted from this point forward. Clinical information will also be collected on discharge. During the one week of test activation for the internal pilot study, we will collect only anonymous data from patients that meet the selection criteria defined in Appendix 1. See Appendix 3 for an example logistics guidance document for operationalising recruitment at study sites. Case Report Forms (CRFs) completed after site registration at https://redcap.medsci.ox.ac.uk/. Patient numbers consist of a 3-or 5-digit site code and a 4-digit patient number. Local investigators should be assigned patient numbers sequentially for each site beginning with 0001. In the case of a single site, recruiting patients on different wards, or where it is otherwise difficult to assign sequential numbers, it is acceptable to assign numbers in blocks. E.g. Outpatient ward will assign numbers from 0001 onwards. In-patient ward will assign numbers from 5001 onwards. The patient identification code is entered at the top of each and every sheet. For settings or circumstances in which resources are constrained, an abbreviated case report form is provided. Follow-up procedures (e.g. serial sampling) will be undertaken only when resources allow according to Tier 2 sampling outlined in Section 3.5. Follow-up procedures will only be undertaken if appropriate biological safety measures can be maintained. Sites unable to perform daily follow-up as described below may reduce the frequency of follow-up procedures or exclude follow-up if necessary. Regular clinical assessment and sampling will follow local guidelines. All patients will have further clinical information recorded in the case report form to record events and treatment experienced during hospitalization and outcome. Some of the samples described below will coincide with clinical management. The number of these will depend on the applicable care guidelines, the treating physician and the health of the patient. Collection of clinical information, blood sample (volume dependent on weight -see Table 6 ), urine, sputum (if possible), stool or rectal swab, infection site and respiratory samples. Collection of clinical information, urine, sputum (if possible), stool or rectal swab, infection site and respiratory samples. Once acute illness is resolved, or once patients are discharged from hospital, sampling will discontinue until the 3 month and 6-month visits. All patients will be asked to return for a convalescent visit and blood sample at 3 months and 6 months post recruitment. Resolution of acute illness is defined as: Clearance of pathogen from appropriate samples, return of systemic inflammatory response to considered 'normal' values and one of: 1) recovery from organ failure(s)/need for organ support, 2) resolution of the presenting complaint(s), 3) return to life-style prior to illness. [Where a pharmacokinetic study is run concurrently with this protocol] Up to 3 additional samples may be obtained at intervals spread throughout the dosing schedule (ideally including one sample immediately before a dose) of the drug being studied. The spread of the samples can be determined on a case-by-case basis to fit in with clinical care; provided the precise times of administration and the precise time of blood sampling are recorded, samples taken at any time will be of use for analysis using population pharmacokinetic methods. Samples will be taken in conjunction with those required for clinical care in order to minimize research-specific intervention. Samples taken outside of the scheduled days can be used for study testing and should be recorded with the accurate sampling date. For respiratory samples for SARI patients, a combined nose and throat swab will be collected from all patients. If a patient is intubated an endotracheal aspirate will also be collected. Also, where resources permit, a Nasopharyngeal aspirate (NPA) OR (if NPA impossible) a flocked nose and throat swab sample will also be collected. A sputum sample will be collected when a productive cough is present, and the patient is able to produce one. Infection site samples are samples of tissue or fluid or swabs taken from infected sites such as an inflamed oropharynx or inflamed conjunctiva. Residual volumes of all other samples taken for clinical care will be stored. Patients enrolled to the study whose illness is subsequently confirmed to be the result of infection with a pathogen which is not relevant to the objectives of this study, and who have no indication or likelihood of co-infection with a relevant pathogen, will be withdrawn. No further follow-up will be conducted. Patient autonomy to withdraw from the study at any time must be respected Appropriate selection and timely collection of high-quality specimens, proper storage procedures and comprehensive diagnostic testing will ensure the quality of data. Local hospital protocols will be used to collect and handle specimens. Guidance on the collection of specimens from patients with emerging infections can be found on the WHO website. In dealing with novel pathogens where little is known about transmissibility and/or virulence, great care must be exercised to ensure the safety of hospital staff and other patients. Strict adherence to collection protocols, biosafety and adequate personal protective equipment (PPE) is essential. Biosafety procedures will be as per local policy/guidance, will be in keeping with any national and/or international regulations, and will be applied to the collection, storage, transfer and laboratory handling of research samples. Emerging or remerging pathogens may be classified as requiring BSL2, BSL3 or BSL4 safety management and guidelines should be consulted as per hospital protocol. In addition, an emergent agent may also be risk assessed as posing a threat to animal health, and may be regulated under the specified animal pathogens order as well. Laboratories planning to participate in the study should consider how they would fulfil a requirement to handle research samples in addition to clinical samples. All samples collected must be labelled according to local hospital policy with appropriate identification (full patient identifiers) and hazard labelling and ideally marked 'ISARIC RESEARCH' with a solvent resistant marker. Samples will be processed as per Table 9 'Processing/storage'. Testing that cannot be done in country may be exported. Samples sent to laboratories other than those listed in the Protocol and Material Transfer Agreement will be anonymised with unique coded identifiers to protect the identity of the patient. National guidance must be adhered to for the transport of specimens Clinical samples will be labelled with standard hospital information, including the date and sent with the standard lab request forms. Residual volumes available after clinical and research testing is complete will be retained by the lab. Where local resources allow, additional information and samples will be sought during treatment with antimicrobial or immunomodulatory therapies in order to investigate the relationship between dose and plasma drug concentrations, to determine the variability in pharmacokinetics in patients receiving these drugs, and to identify the key pharmacokinetic drivers of pharmacodynamic outcomes (measured using pathogen load, inflammatory markers, illness severity scores or drug toxicity). This information will be collected on the pharmacokinetics record form, and includes both the precise (to the minute) times of drug administration and the precise time of blood sampling. Samples obtained will be split as required for pharmacokinetic/pharmacodynamic analysis of each antimicrobial or immunomodulatory therapy prescribed; the volume of blood to be drawn will not increase. Samples will only be processed if authorised biological containment and laboratory facilities appropriate to the relevant pathogen are available. *freeze at -80°C where possible, or at least at -20°C. If necessary (e.g.. weekends) store in refrigerator until processing. Access to samples for additional analyses will be governed by a committee comprising the clinical lead investigators and scientific investigators for this study (the Data and Materials Access Committee), in collaboration with the individual recruiting sites. Linked anonymised data generated during the course of these studies may be shared between investigators. Each local site will hold their own data. Where possible and within the constraints of international law and specific requirements of local ethical and institutional management approvals, data will be shared centrally within one master database held in Oxford, which will be fully compliant with standard data management processes and local regulations. This database will be held on servers. Access to data for outside investigators will be reviewed by the data and materials access committee. Samples will only be stored in containment facilities that have appropriate biological safety measures in place and have received necessary authorisation to store samples (according to national regulations for the pathogen being studied). Samples collected will be used for the purpose of this study as stated in the protocol and consented for future use. The standard consent form will request consent from subjects for sample storage and/or export of specific samples to collaborating institutions for investigations that cannot be performed locally. Any proposed plans to use samples other than for those investigations detailed in this protocol will be submitted to the relevant ethics committees prior to any testing. Collaborating centres must have appropriate biological safety measures and regulatory approvals in place in order to receive samples. Any database detailing clinical data will only identify participants by a participant number. Participant names or any other identifying details will NOT be included. Data may be used alone or in combination with data from related studies in secondary analyses. Data is hosted on REDCap, a secure web platform for building and managing online databases and surveys. Medical management will be according to standard of care at the treating site and not a part of this research protocol. Research interventions include only collection of clinical information and specimens and therefore adverse event reporting is not applicable as there is no intervention. Clinical and laboratory data will be collected throughout the acute illness period according to local resources. Priority at all times will be given to the collection of clinical information. Research data will be integrated as much as possible with information available from hospital and regulatory files. Clinical data will be collected locally with the relevant CRF for SARI, VHF, CNS or other emerging infections of public health interest will be completed by a study staff as appropriate. The data will be anonymised at site and a study number issued. When available, data collected by staff at each site will be submitted electronically to a protected online database. Anonymised data may be entered by study staff in order to minimize the workload on site clinical staff. Quality checks will be built into the data management system and there will be quality control checks of critical data points entered into the CRFs to ensure standardization and validity of the data collected. Patients' identities will be protected and their information held securely. The records kept will not include any information that allows patients to be identified. For the Clinical Characterisation Protocol access to the data entry system will be protected by username and password. Username and password will be assigned during the registration process for individual Site Investigators. All electronic data transfer between study site and database will be username and password protected. Each centre will maintain a trial file including a protocol, ethics approval documentation, and paper CRFs. A participant list will be used in each study site to match identifier codes in the database to individual patients in order to record clinical outcomes and supply any missing data points. The Participant List (enrolment log) is maintained locally and is not to be transferred to any other location. The sites will compile an enrolment log including the patient's name, date of birth, hospital identification number and unique study number. Subsequent data will be identified by the unique patient study number only. The enrolment log and study data will be kept separately. This study will adhere to the research policies of ISARIC (International Severe Acute Respiratory and Emerging Infection Consortium, www.isaric.org). A fundamental principle of this work is that clinical investigators contributing to research efforts, often in extremely difficult circumstances, must be given full recognition for their efforts and the opportunity to access data and samples. Ownership of any data transferred to the eCRF and centralized database will be retained by the site that contributed it. All analysis of pooled data will be undertaken with the explicit agreement of each site who contributed. Data and results from central laboratory analysis for individual patients will be available to the clinicians looking after those patients as soon as possible. Often, this may not be in time to affect treatment decisions. Research data will be shared with public health authorities as needed. Several procedures to ensure data quality and protocol standardisation will help to minimise bias. These include:  A detailed data dictionary will define the data to be collected on the case report form;  Quality checks will be built into the data management system and there will be quality checks of critical data points entered into the CRFs to ensure standardization and validity of the data collected; Data queries may be generated, depending on resource availability. Any information that is not available for the investigator will not be considered as missing. No assumptions will be made for missing data. Data monitoring will be conducted on a randomly selected subset (up to 5%) of cases, through discussion with the local site investigator to discuss data collection techniques. Direct site visits will not be feasible, given the scope of the study. This study is to be conducted during a disease outbreak or presentation of cases of disease of public health interest. This is a challenging research situation because this falls in the area between clinical care, public health and clinical research (WHO Ethical Review in Disease Outbreak Expert Meeting 2009). Normally research activities are defined by anything conducted outside standard clinical care. In these situations, there may be no definitive standard guidelines or treatment protocols and therefore there is often little difference between what can benefit the patients and what is very important for building knowledge on the pathogenesis of the disease to guide future treatment and management. Medical management of participants in this study must never be compromised by study procedures. At all times, priority will be given to samples required for medical management. Research sampling should never compromise the quantity or quality of samples taken for medical management, nor create a significant diversion for clinical teams from the day-to-day care of the patients. This study will be conducted in compliance with the principles set out in the Declaration of Helsinki. Where applicable, the principles of Good Clinical Practice (ICH 1996) and other applicable regulations and guidelines will be used to guide procedures and considerations. This protocol will be reviewed and approved by the ethical and regulatory review boards required by the recruiting site and the study sponsor. No patients will be enrolled until all approvals have been obtained for the applicable site. Consent forms will be provided in plain English. Illiterate participants will have the consent form read in the presence of a witness, who will sign to verify the accurate reading of the form and agreement of the participant. For participants who cannot understand the language of the available forms, verified translations will be made when possible. If it is not possible to prepare a translation in a required language, verbal translation of the document and the consent discussion (if required) will be used. In this case, the translator may act as the witness for consent and sign the consent form so that patients who cannot read the language of the forms are not excluded from this research. In the case of adult participants who are unable to give informed consent due to mental or physical status, the wishes of the participant may be declared by an appropriate consultee according to the site policy on obtaining consent for medical procedures. If, during the course of the study, the participant's status changes such that they are able to consider consent independently, informed consent must be discussed and obtained. Parents or guardians of children under the age of 16 years old will give consent for their child. Study staff obtaining consent will consider the ability of the child to understand the principles of the study and will discuss the study with the child in age appropriate language. Where appropriate, children will be invited to give assent, which will be recorded on the informed consent form. The right to withdraw at any time without negative impact will be reinforced with the child and their parent/guardian. Should the UK rules on consent by young people for research purposes alter during the period of this study to allow consent by competent minors, then these new rules will be applied to this study without further amendment. A copy of the informed consent form will be given to the person who gives consent. Prospective participants are freely able to decline participation in this study or to withdraw from participation at any point without suffering any implied or explicit disadvantage. All patients will be treated according to standard practice regardless of if they participate. Inconvenience. Participation in this research study poses a minimal risk of inconvenience through household visits and attendance of follow-up visits. Appropriate compensation for travel costs to attend follow-up visits and for time of attending visits will be given according to the standard policies of the sponsor. Participants may have blood drawn more often than is required for standard care. Phlebotomy can be associated with pain at the draw site and rarely with infection. Daily blood draw volumes have been restricted according to weight so that combined clinical and research sampling is within recommended limits. Discomfort will be minimized by having expert staff obtain blood samples, and by combining research sampling with routine clinical sampling, where possible, which normally occurs daily in acutely unwell patients in hospital. Collecting respiratory swabs may be cause transient discomfort. Discomfort and risk will be minimized by using experienced clinical staff at each site, and samples will be taken at the same time as clinical samples in order to minimize these risks. Collection of cerebrospinal fluid with lumbar puncture will only be performed if clinically indicated, as decided by the responsible physician. Clinical investigations are the priority, with any remaining sample collected for use in research. Guidance on the safe recommended daily total volume of CSF to take in different age groups is provided (Table 7) . Lumbar puncture can be associated with discomfort at the site of needle insertion, headache, and rarely bleeding or infection. This study includes genetic testing to identify host genetic variants associated with disease progression or severity. There is a very small chance that these tests may result in the incidental discovery of information that is relevant to the participant's health. Since the samples will be analysed anonymously in batches, and generally in non-clinical laboratories with investigational techniques, we will not attempt to identify and inform participants of any results from genetic tests. If we were to do so, there would be a considerable risk of accidental harm in the form of unnecessary anxiety and distress. Specific risks for VHF patients Participants with VHF may be at increased risk of bleeding from venepuncture sites. The decision to perform venepuncture for research purposes will only be performed following discussion with the attending clinician and only if venepuncture is deemed not to pose unacceptable risk to the patient and/or staff. When at risk venepuncture will be minimised by limiting research venepuncture to coincide with clinical venepuncture. There will be no direct benefit to research participants. The study may include biological sampling in addition to sampling required for medical management. The results of the tests done on these samples may not contribute to improving the participant's health. The results of this study will not be available in time to contribute to the participant's care. Where possible, test results with potential relevance to patient care will be informed to the participant and/or treating doctor. The feasibility of this will depend on local resources. Some assays cannot immediately benefit the patient because data will need to be pooled with others, or because the assays take time. Particularly in the case of emerging infections, it is likely that other research projects, including clinical trials, will also recruit participants in this study. In fact, it is important that they do so, and great effort has been expended to ensure that this observational study is compatible with, and complementary to, other possible research projects. This study will be conducted by clinical staff and those involved in the study will ensure that each study participant's privacy and confidentiality is maintained. Participants will not be identified in any published reports of this study. All records will be kept confidential to the extent provided by international and local law. All laboratory specimens, evaluation forms, reports, study protocol, documentation, data and all other information generated will be held in strict confidence. No information concerning the study, or the data will be released to any unauthorized third party. Paper and electronic medical records may be accessed during the study to confirm, verify or complete clinical information provided in the case report form. Site files will at all times be accessible only to clinical and research staff. Consent will be sought for investigators to access patient data. Local research staff will access personal information, but all data will be pseudo-anonymised before transfer by eCRF. It is important that data generated now is not destroyed unnecessarily, since they will be of considerable potential value to future generations faced with similar outbreaks of infectious disease. Electronic data and electronic copies of paper documents will be stored for at least 5 years. Custody of site data will remain with the responsible physician at the site. Samples may be shipped (depending upon pathogen of interest) to a reference laboratory for analysis as approved by the appropriate ethics/institutional review committee. Any residual sample will remain in the custody of the site until use can be decided upon. Recruitment of critically ill patients who are not able to consent. This is a ubiquitous problem in acute and critical care research and there is a clear legal framework under which these patients may be recruited to research studies. In all cases, efforts will be made to obtain informed consent from patients early in the course of illness, before critical illness interferes with their capacity to make decisions and to confirm consent at the earliest point in recovery. This principle applies equally to adults and children. Perceived coercion because of individual responsibilities to society, and the implications of this research for public health. We are sensitive to the fact that some patients or their representatives may feel under an unusually strong moral obligation to participate given the nature of this research and the wide, and often inaccurate, publicity surrounding emerging infections. In view of this, we have tried to make both the potential benefits and limitations of this simple observational study clear in the information sheet. In the informed consent form we also stress that participation is entirely voluntary and there is no penalty of any kind for declining to join the study. Balance between public health and research. Patients with emerging infections are commonly the subject of public health investigations. The work proposed here is research and will be clearly presented as such. There is no primary gain to the patient from participating. In designing and describing this research we are clear that, in accordance with the guiding principles of Good Clinical Practice, the needs and autonomy of the individual are paramount and the potential benefits to wider society do not take precedence. Risks to clinical and research staff treating the participants. Staff who enrol, examine and take samples from study patients are at risk of infection. Care of study participants will require increased sampling and contact frequency added to normally heavy clinical workloads. All staff must be trained in recognised infection control measures and have ready access to appropriate personal protective equipment. In collaboration with the public health authorities, there will be on-going communication with hospital staff to ensure the appropriate training is given, to support the work and to ensure that there is no excess burden on the health system. Where appropriate, dedicated research staff will be available to support the study activities. The proposed research is the product of several years of discussion within a group of international experts who were brought together following the 2009 influenza pandemic to plan the global research response to future severe and emerging infections: the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC). ISARIC working group 3 (genomics, pathogenesis and pharmacology) comprised senior clinical scientists from 5 continents working together to promote and harmonise observational research during outbreaks of severe infectious disease. For maintenance of the Clinical Characterisation Protocol. To be used in combination with this protocol. An online interactive presentation of the information contained in the following tables is available at: https://isaric.net/ccp/ Weekly until max 100 days 3 months and 6 months after recruitment >40kg R P S P S P S P S P S P S P S S C 20 to 40kg R P S P S P S P S P S P S P S S C 10 to 20kg R P S P S P S P S P S P S P S S C 4 to 10kg R P S P S P P P S P P P S P P S C <4kg R P S P S P P P S P P P S P P S C Sample priority 1 11 2 11 5 11 7 11 3 11 8 11 10 11 9 6 4 In the event that local resource limitations require sampling frequency to decrease, samples will be prioritised as shown (1=highest priority). Serial sampling will stop when acute illness resolves, or a patient is discharged from hospital: next samples taken will be the blood sample at 3 months and 6 months post recruitment. Team IC-. COVID-19 in critical care: epidemiology of the first epidemic wave across England, Wales and Northern Ireland Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region International variation in the management of severe COVID-19 patients Characterisation of the first 250,000 hospital admissions for COVID-19 in Brazil: a retrospective analysis of nationwide data Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study Clinical features, ventilatory management, and outcome of ARDS caused by COVID-19 are similar to other causes of ARDS Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study Semple MG, Noursadeghi M, Investigators IC. Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study COVID-19: First Do No Harm Optimizing the Trade-off Between Learning and Doing in a Pandemic Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis Dexamethasone in Hospitalized Patients with Covid-19 Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clinical microbiology and infection : the official publication of the Potential health and economic impacts of dexamethasone treatment for patients with COVID-19 Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a propensity score matching study Critical Care Utilization for the COVID-19 Outbreak in Lombardy, Italy: Early Experience and Forecast During an Emergency Response Effects of nurseto-patient ratio legislation on nurse staffing and patient mortality, readmissions, and length of stay: a prospective study in a panel of hospitals Expanding ICU facilities in an epidemic: recommendations based on experience from the SARS epidemic in Hong Kong and Singapore International Surviving Sepsis Campaign guidelines 2016: the perspective from low-income and middle-income countries Research Studies / Co-enrolment Appendix 1: Test Activation Guidance -Internal Pilot Study Appendix 2: Full biological sampling schedules (Tier 1 and Tier 2 schedule 2-11) Example logistics guidance document for recruiting sites A virtual site visit is available at https://isaric.net/4c/virtual_site_visit Aim: recruit hospitalised cases of confirmed COVID-19, as early as possible.Consent: once the form is signed by a participant it is hazardous. To record consent, we suggest an independent witness observes the completed form then signs a fresh copy outside of the isolation area. Telephone proxy consent is acceptable if relatives are unable to attend the hospital.Sampling pack will be sent from [**hq_contact_details**]. This will contain blood RNA tubes, "SAM" strips for nasal sampling, "Oracol" swabs for oral fluid collection, barcode labels and CatB shipment containers.Obtain samples according to the schedule. You can find out which tier you are operating at in the front page of the site file.If you have capacity to recruit at TIER 2: Day 1 2 3 4 5 6 7 8 9 28 days after recruitment Sample priority 1 2 3 4 R: recruitment sample; S: serial sample; C: convalescent sample.If for any reason a sample cannot be collected on a given day, collect at the next opportunity.If unable to collect all planned samples, 'sample priority' denotes the relative priority of each set of samples.If patient is discharged before day 9, the day 9 sample set can be omitted.Or if your centre is recruiting at TIER 1: Day 1 2 3 4 5 6 7 8 9 28 days after recruitment Samples R Case report form data should be entered electronically at https://ncov.medsci.ox.ac.uk/ using the REDCap platform. Complete the core form on day 1, the daily form on alternate days thereafter and the outcome form on discharge/death. Prior to donning PPE and entering isolation, label sample collection containers as follows:(i) 5 digit site code + 4 digit patient code (see below) -using a solvent resistant marker (ii) "ISARIC" -using a solvent resistant marker (iii) unique barcode label (not for clotted or EDTA blood tubes)Ensure labels do not cover the whole tube: a clear window into the full length of the tube is essential for processing.All samples should be double-bagged after collection and handled per local clinical and laboratory procedures. PATHOGEN samples should be doubled bagged separately from the BLOOD samples. This is because PATHOGEN samples will go straight to freezer storage without further handling to comply with PHE Guidance, while some BLOOD samples will require processing before storage.The 'Transport of Samples' form should be filled out for each sample set with study number, collection date, timepoint, samples obtained and the unique barcodes corresponding to each sample (stick in copy of barcode sticker). All data records entered on the REDCap system must be anonymised using a five-digit site code then sequential four-digit patient number e.g. 0001 and so on. Please maintain an electronic log of samples obtained (patient study number, sample type, date obtained, timepoint) The Roslin Institute, University of Edinburgh Centrifuge 1500g for 10mins, ideally at +4°C.  serum (3x 1mL aliquots; store -80°C b ) Centrifuge 1500g for 10mins, ideally at +4°C.  plasma (3x 1mL aliquots; store -80°C b )  cell pellet (1x 1mL aliquot; store -80°C b ) leave the cell pellet in the EDTA tube and store -80°C b No processing required. Freeze at -20°C; transfer to -80°C after 24h where possible.a Pathogen samples: swabs in VTM, respiratory secretions, urine or stool. b Freeze at -80°C where possible, or at least at -20°C. Aliquots must be stored in screw-cap vials, not flip-top tubes.Label aliquots with:(i) 5 digit site code + 4 digit patient code -using a solvent resistant marker (ii) "ISARIC" -using a solvent resistant marker (iii) "S" = serum; "P" = plasma; "C" = cell pellet -using a solvent resistant marker (iv) unique barcode label Please do not label samples with any patient identifiable information. PHE have issued guidance on appropriate biosafety levels for handling specimens from patients with COVID-19: https://www.gov.uk/government/publications/wuhan-novel-coronavirusguidance-for-clinical-diagnostic-laboratories/wuhan-novel-coronavirus-handling-andprocessing-of-laboratory-specimens  Section 5.1 Processing of respiratory tract specimens, faecal specimens, urine specimens, and tissue specimens in which virus has not been inactivated should be conducted at BSL3. No such processing is required for this protocol. These samples should remain double bagged and frozen pending transport to the MRC-University of Glasgow Centre for Virus Research. Section 5.2 Accordingly, processing of whole blood, including aliquoting of serum and plasma can be conducted at BSL2, as long as it is consistent with the terms of the local risk assessment. Section 6 Manual centrifugation of specimens with infectious potential must be performed using sealed centrifuge rotors or sample cups. Rotors or cups should be loaded and unloaded in a Microbiology Safety Cabinet. Label the outer transport container with the sender's and recipient's name and address. If preprinted labels are not supplied the recipient details are as follows:[**hq_contact_details**]